Medical Disclaimer

Compounded GLP-1 Medications: Regulatory Position

Compounded semaglutide, compounded tirzepatide, and other compounded GLP-1 preparations covered on this site are NOT FDA-approved finished drug products. They are not the same as:

• Wegovy® (semaglutide) — FDA-approved for chronic weight management
• Ozempic® (semaglutide) — FDA-approved for type 2 diabetes
• Zepbound® (tirzepatide) — FDA-approved for chronic weight management
• Mounjaro® (tirzepatide) — FDA-approved for type 2 diabetes
• Rybelsus® (oral semaglutide) — FDA-approved for type 2 diabetes

Compounded preparations are not bioequivalent to FDA-approved brand-name medications in the FDA-regulatory sense. They share the same active molecule but differ in regulatory framework, manufacturing standards, and quality control.

Compounding Framework

Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. They are dispensed by:

• 503A pharmacies — patient-specific compounding under state Board of Pharmacy oversight
• 503B outsourcing facilities — FDA-registered facilities producing under cGMP-like standards

What GLP-1 Price Guide Does Not Do

• We do not prescribe medication
• We do not provide medical advice for individual patients
• We do not recommend specific medications for individual clinical situations
• We do not endorse any particular GLP-1 provider as medically superior
• We do not guarantee outcomes from any GLP-1 treatment
• We do not provide diagnostic services

What This Site Is For

GLP-1 Price Guide provides:

• Pricing transparency analysis across telehealth providers
• Educational content on GLP-1 pricing structures
• Editorial coverage of compounded GLP-1 regulations
• Provider comparison data sourced from publicly available pages
• Resources to help patients ask informed questions of their healthcare providers

If You Are Considering GLP-1 Treatment

Consult a licensed healthcare provider. Discuss your individual medical history, contraindications, and treatment goals. The decision to start, continue, or discontinue GLP-1 medications must be made with a licensed clinician based on your specific clinical situation.

Investigational Medications (Retatrutide)

Some content on this site covers investigational medications (including retatrutide) that are not commercially available. These medications are available only through clinical trial participation. GLP-1 Price Guide does not recommend purchasing investigational medications from any online source.

Research-Use-Only Vendors

Vendors selling "research peptide" or "research use only" GLP-1 analogs for human therapeutic use are operating outside lawful pharmaceutical channels. The FDA has issued warning letters to multiple such vendors. GLP-1 Price Guide does not recommend research-peptide vendors for therapeutic use.

Adverse Events

If you experience adverse events from any GLP-1 medication, contact your prescribing clinician immediately. Report serious adverse events to the FDA MedWatch program (1-800-FDA-1088 or fda.gov/medwatch).

Trademark Notice

Wegovy®, Ozempic®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Mention of brand names on this site is for informational and comparative purposes only and does not constitute endorsement by the trademark holders.

Pricing Disclaimer

Pricing information may change. Always verify current pricing directly with each provider before enrolling. We do not guarantee the accuracy of any pricing figure at any future point. Pricing was reviewed: June 1, 2026.